NCT01416974View on ClinicalTrials.gov

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 22, 2011

Primary Completion Date

January 7, 2019

Study Completion Date

January 7, 2019

Conditions
Leukemia
Interventions
DRUG

cyclophosphamide

Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.

BIOLOGICAL

modified T cells

followed by consolidative therapy with the modified T cells in 3 planned cohorts.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01416974 - Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab | Biotech Hunter | Biotech Hunter